Acumen Pharmaceuticals (ABOS) Common Equity (2020 - 2026)
Acumen Pharmaceuticals (ABOS) posted Common Equity of $87.5 million for Q1 2026, up 24.2% sequentially from $70.4 million in Q4 2025, and down 43.75% YoY from $155.5 million in Q1 2025.
Acumen Pharmaceuticals (ABOS) Common Equity (2020 - 2026) Analysis & Trends
Acumen Pharmaceuticals has reported Common Equity for 7 years, with the latest figure at $87.5 million in Q1 2026.
- Quarterly Common Equity fell 43.75% year-over-year to $87.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $87.5 million (down 43.75% YoY) and the FY2025 annual result came in at $70.4 million, down 61.26% from the prior year.
- Common Equity rose to $87.5 million in Q1 2026 per ABOS's latest filing, from $70.4 million in the prior quarter.
- Over five years, Common Equity peaked at $280.3 million in Q3 2023 and troughed at $70.4 million in Q4 2025.
- A 5-year average of $184.2 million and a median of $188.8 million in 2022 frame the typical range for Common Equity.
- The sharpest annual moves came in 2022 and 2025: Common Equity surged 575.32% in 2022, then slumped 61.26% in 2025.
- Over 5 years, Common Equity stood at $188.8 million in 2022, then surged by 41.42% to $267.0 million in 2023, then slumped by 31.9% to $181.8 million in 2024, then plunged by 61.26% to $70.4 million in 2025, then advanced by 24.2% to $87.5 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $87.5 million, $70.4 million, and $93.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Acumen Pharmaceuticals | 226.87 Mn | 226.87 Mn | - | 57.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 57.26 Mn |
| Mar 31, 2026 | 87.48 Mn |
| Dec 31, 2025 | 70.43 Mn |
| Sep 30, 2025 | 93.17 Mn |
| Jun 30, 2025 | 117.08 Mn |
| Mar 31, 2025 | 155.52 Mn |
| Dec 31, 2024 | 181.82 Mn |
| Sep 30, 2024 | 217.20 Mn |
| Jun 30, 2024 | 243.95 Mn |
| Mar 31, 2024 | 262.03 Mn |
| Dec 31, 2023 | 266.97 Mn |
| Sep 30, 2023 | 280.27 Mn |
| Jun 30, 2023 | 168.87 Mn |
| Mar 31, 2023 | 179.09 Mn |
| Dec 31, 2022 | 188.78 Mn |
| Sep 30, 2022 | 196.65 Mn |
| Jun 30, 2022 | 206.52 Mn |
| Mar 31, 2022 | 216.09 Mn |
| Dec 31, 2021 | 225.18 Mn |
| Sep 30, 2021 | 233.36 Mn |